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Diabetes and Coronary Disease
A Need for New Therapies
for an Expanding Disease Burden*
Wilbur Y. W. Lew, MD,
Anthony N. DeMaria, MD
San Diego, California
The prevalence of diabetes mellitus (DM) has nearly dou-
bled in the adult population of the United States from 4.5%
in 1995 to 8.2% in 2010 (1). Patients with DM are more
likely to develop cardiovascular disease, have shorter life
expectancy (2), and have higher mortality from acute coro-
nary syndromes (ACS) (3). The marked rise in a risk factor
with such adverse consequences on coronary artery disease
(CAD) has created a global disease burden with an urgent
need to find new therapeutic approaches to treat CAD in
patients with DM.
See page 2038
The clinical presentation of myocardial ischemia in pa-
tients with DM varies from typical angina pectoris, to
atypical angina (e.g., exertional shortness of breath), to
asymptomatic episodes of silent ischemia. In a post hoc
analysis of the BARI 2D (Bypass Angioplasty Revascular-
ization Investigation 2 Diabetes) trial, there was no differ-
ence in 5-year mortality, or composite of death, myocardial
infarction, or stroke depending on whether patients with
DM and myocardial ischemia had angina, angina equiva-
lent, or no symptoms (4). The prognostic implications
of symptoms is less important than the presence of
ischemia, which is particularly relevant for patients with
DM who are susceptible to have silent ischemia (5). In
ACS, the presence of ischemia recorded by continuous
electrocardiogram for 7 days is an independent risk factor
for cardiovascular death after 1 year (6). This was similar
for patients with or without DM.
The management of CAD with or without DM includes
cornerstone guidelines for controlling ischemic symptoms
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ers (7). These agents decrease myocardial ischemia by
decreasing the major determinants of myocardial oxygen
demands and/or by increasing coronary blood flow to the
ischemic myocardium. Newer antianginal agents have
mechanisms related to modulating myocardial metabolism
or by inhibiting ion channels (8).
Ranolazine is an inhibitor of the late sodium channel
current with antianginal effects and the additional benefit of
improving glycemic control (9). Ranolazine has been shown
to decrease angina in stable CAD in randomized, double-
blind trials as a monotherapy (MARISA [Monotherapy
Assessment of Ranolazine in Stable Angina] trial) (10), or
in combination with beta-blocker or a calcium-channel
blocker (CARISA [Combination Assessment of Ranolazine
in Stable Angina] and ERICA [Efficacy of Ranolazine in
Chronic Angina] trials) (11, 12). In 2 substudies, ranolazine
decreased hemoglobin A1c (HbA1c) levels in patients with
M treated for chronic angina ischemia for 12 weeks
CARISA trial) (13) or ACS for 4 months (MERLIN–
IMI 36 [Metabolic Efficiency With Ranolazine for Less
schemia in Non-ST-ElevationThrombolysis In Myocar-
ial Infarction-36]) (14). Thus, ranolazine may be particu-
arly well suited for treating CAD in patients with DM.
In this issue of the Journal, Kosiborod et al. (15) per-
ormed an international, double-blind trial in 949 CAD
atients with type 2 DM and stable angina treated with 1 or
antianginal drugs who were randomized to 8 weeks of
reatment with ranolazine versus placebo. Patients treated
ith ranolazine had fewer episodes of angina (3.8 vs. 4.3
pisodes/week) and less use of sublingual nitroglycerin (1.7
s. 2.1 doses/week) from weeks 2 to 8 compared with
lacebo. The benefits of ranolazine were more prominent in
atients with higher than lower HbA1c, with a statistically
ignificant interaction at several different cutpoints for
bA1c.
The strengths of this study are the clear evidence that
ranolazine can decrease the frequency of episodes of angina
and nitroglycerin use. Although this confirms prior post
hoc analyses of subgroups from the CARISA (13) and
MERLIN–TIMI 36 (14) trials, this provides stronger
evidence in a prospective trial. It should be noted that this
was a short-term (8-week) study. The major study limita-
tion is that the absolute effects, although statistically signif-
icant, were small. Ranolazine resulted in only 0.5 fewer
episodes of angina and 0.4 fewer sublingual nitroglycerin
tablets used per week. Quality of life measures were not
statistically significantly altered. The clinical relevance of
such slight absolute differences may be questioned.
The results in this stable CAD population provide proof
of concept that this antianginal medication with a unique
mechanism of action is beneficial, can be added to other
well-established antianginal drugs, and is particularly effec-
tive with higher HbA1c levels. This is especially relevant for
AD patients with DM, who may have more limited
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on medical management.
Although intriguing, it is unknown why ranolazine had
greater benefits in patients with higher HbA1c levels. It is
possible that patients with poorer control of DM have more
severe CAD or endothelial dysfunction. In a small study,
ranolazine improved endothelial function in patients with
DM (16). The benefits of ranolazine may be related to
glucose raising effects, or raising the threshold for angina.
Although decreasing angina can improve the quality of life,
it will be important to establish that ranolazine decreases
myocardial ischemia as well, as this is a relevant determinant
of outcomes.
It is important to dissect out if ranolazine has preferential
benefits in DM that are related to this drug class by
inhibiting the late sodium channel current and/or related to
improving glycemic control. This would help to determine
the appropriate combination of drugs and to design new
therapies that specifically target CAD in patients with DM.
This and other therapeutic advances will be required to
manage the explosion of disease burden related to DM.
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